PTCL: Clinical Trials

3 trials for PTCL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Unknown 3
Phase 11Unknown 1

Follow PTCL: new trials by email Literature Review of PTCL trials Research Report on PTCL

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma
Toripalimab, chidamide - PTCL
Phase 2UnknownCancer Institute and Hospital, Chinese Academy of Medical Sciences432024-04-032024-07-09
Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL
Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib
Phase 1 / Phase 2UnknownFudan University302022-03-012022-02-14
A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
YY-20394 treatment - PTCL
Phase 2UnknownShanghai YingLi Pharmaceutical Co. Ltd.902021-04-012021-01-12

Interventions

Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1)  ·  Vincristine (1)  ·  parsaclisib (1)  ·  toripalimab (1)

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  Fudan University (1)  ·  Shanghai YingLi Pharmaceutical Co. Ltd. (1)

Countries

China (1)

Top investigators

Junning Cao (1)